Additional file 1: of Serum KL-6 levels reflect the severity of interstitial lung disease associated with connective tissue disease

Figure S1. Receiver operating characteristic curve to demonstrate optimal cut-off value of KL-6 to detect presence of ILD in CTD. Figure S2 ROC curves to evaluate the association between semiquantitative CT grade of ILD and the measurement of KL-6, FVC%, and DLCO%. Table S1. Prediction of CTD-ILD progression in a subgroup with follow-up data. (DOCX 200 kb

Targeted Chemo-Photothermal Treatments of Rheumatoid Arthritis Using Gold Half-Shell Multifunctional Nanoparticles

We have developed RGD-attached gold (Au) half-shell nanoparticles containing methotrexate (MTX) for the treatment of rheumatoid arthritis (RA), where MTX is the most widely used disease-modifying anti-rheumatic drug (DMARD) for the treatment of RA, and RGD peptide is a targeting moiety for inflammation. Upon near-infrared (NIR) irradiation, heat is locally generated due to Au half-shells, and the drug release rate is enhanced, delivering heat and drug to the inflamed joints simultaneously. RA is a chronic inflammatory disease characterized by synovial inflammation in multiple joints within the penetration depth of NIR light. When combined with NIR irradiation, these nanoparticles containing a much smaller dosage of MTX (1/930 of MTX solution) showed greater therapeutic effects than that of a conventional treatment with MTX solution in collagen-induced arthritic mice. This novel drug delivery system is a good way to maximize therapeutic efficacy and minimize dosage-related MTX side effects in the treatment of RA. Furthermore, these multifunctional nanoparticles could be applied to other DMARDs for RA or other inflammatory diseases

Targeted Chemo-Photothermal Treatments of Rheumatoid Arthritis Using Gold Half-Shell Multifunctional Nanoparticles

We have developed RGD-attached gold (Au) half-shell nanoparticles containing methotrexate (MTX) for the treatment of rheumatoid arthritis (RA), where MTX is the most widely used disease-modifying anti-rheumatic drug (DMARD) for the treatment of RA, and RGD peptide is a targeting moiety for inflammation. Upon near-infrared (NIR) irradiation, heat is locally generated due to Au half-shells, and the drug release rate is enhanced, delivering heat and drug to the inflamed joints simultaneously. RA is a chronic inflammatory disease characterized by synovial inflammation in multiple joints within the penetration depth of NIR light. When combined with NIR irradiation, these nanoparticles containing a much smaller dosage of MTX (1/930 of MTX solution) showed greater therapeutic effects than that of a conventional treatment with MTX solution in collagen-induced arthritic mice. This novel drug delivery system is a good way to maximize therapeutic efficacy and minimize dosage-related MTX side effects in the treatment of RA. Furthermore, these multifunctional nanoparticles could be applied to other DMARDs for RA or other inflammatory diseases

Targeted Chemo-Photothermal Treatments of Rheumatoid Arthritis Using Gold Half-Shell Multifunctional Nanoparticles

We have developed RGD-attached gold (Au) half-shell nanoparticles containing methotrexate (MTX) for the treatment of rheumatoid arthritis (RA), where MTX is the most widely used disease-modifying anti-rheumatic drug (DMARD) for the treatment of RA, and RGD peptide is a targeting moiety for inflammation. Upon near-infrared (NIR) irradiation, heat is locally generated due to Au half-shells, and the drug release rate is enhanced, delivering heat and drug to the inflamed joints simultaneously. RA is a chronic inflammatory disease characterized by synovial inflammation in multiple joints within the penetration depth of NIR light. When combined with NIR irradiation, these nanoparticles containing a much smaller dosage of MTX (1/930 of MTX solution) showed greater therapeutic effects than that of a conventional treatment with MTX solution in collagen-induced arthritic mice. This novel drug delivery system is a good way to maximize therapeutic efficacy and minimize dosage-related MTX side effects in the treatment of RA. Furthermore, these multifunctional nanoparticles could be applied to other DMARDs for RA or other inflammatory diseases

Flowchart for patient inclusion.

*, including stomach cancer (n = 2), hepatocellular cancer (1), colon cancer (1), multiple myeloma (1), gastrointestinal stromal tumor (1), and ulcerative colitis (1). ADT, androgen deprivation therapy.</p

Effect of androgen-deprivation therapy (ADT) on the longitudinal serum uric acid (SUA) change in the whole population and post-matched population.

Effect of androgen-deprivation therapy (ADT) on the longitudinal serum uric acid (SUA) change in the whole population and post-matched population.</p

Longitudinal changes in serum urate (SUA) levels according to the subgroups.

Hyperuricemia (SUA ≥7.0 mg/dL), normouricemia (4.0≤ and <7.0 mg/dL), and hypouricemia (<4.0 mg/dL) were defined by using the baseline SUA levels. P values were corrected by the Bonferroni method. * p <0.05 between the baseline and 6-month time points; †, p <0.05 when compared between the surgery and ADT groups at each time point.</p

Effect of the interaction between a specific clinical factor and time on the longitudinal serum uric acid (SUA) levels.

Effect of the interaction between a specific clinical factor and time on the longitudinal serum uric acid (SUA) levels.</p

Baseline peripheral blood neutrophil-to-lymphocyte ratio could predict survival in patients with adult polymyositis and dermatomyositis: A retrospective observational study - Fig 4

<p><b>Survival curves for overall survival in patients with idiopathic inflammatory myopathy, stratified by low/high NLR (A) and CAR (B).</b> NLR, neutrophil-to-lymphocyte ratio; CRP, C-reactive protein; CAR, CRP-to-albumin ratio.</p

Influence of androgen deprivation therapy on serum urate levels in patients with prostate cancer: A retrospective observational study - Fig 2

Longitudinal changes in the serum urate (SUA, A), blood urea nitrogen (BUN, B), serum creatinine (C), total protein (D), albumin (E), and total cholesterol (F) levels. P values were corrected by the Bonferroni method. * p <0.05 between the baseline and 6-month time points; †, p <0.05 when compared between the surgery and ADT groups at each time point.</p